

**PRODUCT INFORMATION**

|   |   |
|---|---|
| <b>Clone ID</b>                         | 1A12  |
| <b>Target</b>                           | Dxd   |
| <b>Synonyms</b>                         | N.A.  |
| <b>Host Species</b>                     | Rabbit  |
| <b>Description</b>                      | PE-conjugated Anti-Dxd antibody(1A12); Rabbit mAb   |
| <b>Delivery</b>                         | Under Development   |
| <b>Uniprot ID</b>                       | N.A.  |
| <b>IgG type</b>                         | Rabbit IgG  |
| <b>Clonality</b>                        | Monoclonal  |
| <b>Reactivity</b>                       | N.A.  |
| <b>Applications</b>                     | Flow Cyt  |
| <b>Recommended Dilutions</b>            | Flow Cyt 1:100  |
| <b>Purification</b>                     | Purified from cell culture supernatant by affinity chromatography   |
| <b>Formulation &amp; Reconstitution</b> | Liquid□PBS with 0.05% Proclin300, 1% BSA  |
| <b>Storage &amp; Shipping</b>           | Store at 2°C-8°C for 6 months   |
| <b>Background</b>                       | Dxd is a potent anti-cancer drug, acting as an alkaloid camptothecin analog and a DNA topoisomerase I inhibitor. It forms a stable complex with topoisomerase I and DNA, impeding DNA replication and inducing cancer cell death. Dxd is utilized as a payload in specific antibody-drug conjugates (ADCs), with examples such as trastuzumab deruxtecan targeting HER2 and patritumab deruxtecan targeting HER3. |
| <b>Usage</b>                            | Research use only   |
| <b>Conjugate</b>                        | PE-conjugated   |
| <b>DIMA Disclaimer</b>                  | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.  |

